Automate Your Wheel Strategy on TMDX
With Tiblio's Option Bot, you can configure your own wheel strategy including TMDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TMDX
- Rev/Share 15.6663
- Book/Share 9.3799
- PB 12.6835
- Debt/Equity 1.4439
- CurrentRatio 9.8575
- ROIC 0.0916
- MktCap 4025207186.0
- FreeCF/Share 0.5117
- PFCF 231.9737
- PE 56.3008
- Debt/Assets 0.5158
- DivYield 0
- ROE 0.2802
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TMDX | JP Morgan | Overweight | Neutral | $116 | $75 | Dec. 17, 2024 |
| Initiation | TMDX | Robert W. Baird | -- | Outperform | -- | $200 | Sept. 24, 2024 |
| Initiation | TMDX | Needham | -- | Buy | -- | $208 | Aug. 21, 2024 |
News
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
Read More
Live Earnings: Will TransMedics (TMDX) Rally After Earnings?
Published: July 30, 2025 by: 24/7 Wall Street
Sentiment: Neutral
TransMedics Group reports its Q2 earnings after the bell. Wall Street current expectations stand at: Revenue: $147.74 million Adjusted EPS: $.43 We'll be updating this live blog with updates during the trading day and then once earnings hit the newswires will post a flurry of news and analysis.
Read More
Why TransMedics Remains A Buy Into 2026
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics beat Q1 2025 estimates and raised full-year guidance, showing strong revenue and earnings growth. The company holds a unique market position with the only FDA-approved system for heart, lung, and liver transport. Profitability and margins are improving, though free cash flow, dilution, and a limited TAM remain concerns.
Read More
TransMedics: Q2 Analyst Estimates Will Fall Short
Published: July 14, 2025 by: Seeking Alpha
Sentiment: Neutral
TransMedics has rebounded from a sharp sell-off by consistently beating guidance and demonstrating strong execution, restoring investor confidence. I anticipate Q2 2025 will deliver another earnings beat, with flight activity data suggesting sales could surpass analyst estimates. The company is showing clear operating leverage, manageable debt, and is building a vertically integrated logistics network in a niche market.
Read More
Is TransMedics Stock a Buy After Short-Seller Drama?
Published: July 03, 2025 by: The Motley Fool
Sentiment: Positive
Explore the exciting world of TransMedics (TMDX 0.97%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Read More
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics Group, Inc. (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach Out
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Read More
TransMedics: Extremely Undervalued And Extremely Innovative
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics delivered a stellar Q1, beating revenue and EPS estimates, and raised FY25 guidance, showcasing robust growth and execution. I see significant upside from expanding organ utilization, especially with the upcoming kidney market and international opportunities, which meaningfully increase TAM. Despite risks like share dilution, logistics complexity, and regulatory hurdles, TMDX's moat and growth trajectory remain compelling.
Read More
Earnings Estimates Moving Higher for TransMedics (TMDX): Time to Buy?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
What Makes TransMedics (TMDX) a New Buy Stock
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics (TMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.
Read More
TransMedics: Exceptional Q1 Undermines The Short Narrative
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics reported extremely strong Q1 results, alleviating concerns from a weak Q3 2024 and a short attack in January. The company continues to expand its logistics capabilities and should see a boost from new heart and lung devices later in the year. While new perfusion devices are set to enter the market, TransMedics' competitive positioning appears to be extremely strong.
Read More
TransMedics Group, Inc. (TMDX) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Bill Plovanic - Canaccord Justin Wang - Morgan Stanley Chris Pasquale - Nephron Research Suraj Kalia - Oppenheimer David Rescott - Baird Mike Matson - Needham & Company Josh Jennings - TD Cowen Operator Good afternoon, and welcome to TransMedics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a …
Read More
3 Mid-Cap Medical Stocks Outperforming the Market
Published: May 06, 2025 by: MarketBeat
Sentiment: Positive
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.
Read More
Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: April 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Stockholders to Learn More About the Investigation
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
Scott+Scott Attorneys at Law LLP Reminds Investors that It is Investigating Ibotta, Inc. (NYSE: IBTA)
Published: April 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Ibotta, Inc. (“Ibotta” or the “Company”) (NYSE: IBTA) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.
Read More
Levi & Korsinsky Notifies Shareholders of TransMedics Group, Inc.(TMDX) of a Class Action Lawsuit and an Upcoming Deadline
Published: April 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=143173&wire=1 or contact Joseph E. Levi, Esq.
Read More
Shareholders of TransMedics Group, Inc. Should Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights - TMDX
Published: April 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=143156&wire=1 or contact Joseph E. Levi, Esq.
Read More
TMDX Deadline Today: Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action First Filed by the Firm – TMDX
Published: April 15, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any out of.
Read More
TMDX DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages TransMedics Group, Inc. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action First Filed by the Firm – TMDX
Published: April 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
Class Action Filed Against TransMedics Group, Inc. (TMDX) - April 15, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=142991&wire=1 or contact Joseph E. Levi, Esq.
Read More
TMDX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action First Filed by the Firm - TMDX
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 14, 2025 / WHY: New York, N.Y., April 14, 2025.
Read More
About TransMedics Group, Inc. (TMDX)
- IPO Date 2019-05-02
- Website https://www.transmedics.com
- Industry Medical - Devices
- CEO Waleed H. Hassanein
- Employees 728